ACR Appropriateness Criteria® on Hodgkin's Lymphoma-Favorable Prognosis Stage I and II

Journal of the American College of Radiology

Volumn 5, Issue 10, 2008, Pages 1054-1066

  Das, Prajnan ^a   Ng, Andrea ^b   Constine, Louis S ^c   Hodgson, David C ^d   Mendenhall, Nancy P ^e   Morris, David Eric ^f   Yunes, Michael J ^g   Chauvenet, Allen R ^h   Hudson, Melissa M ⁱ   Winter, Jane N ^j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF FLORIDA   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g BAYSTATE MEDICAL CENTER   (United States)

^h West Virginia University School of Medicine Charleston   (United States)

ⁱ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

chemotherapy; Hodgkin's lymphoma; involved field; late toxicity; radiation therapy; second malignancy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE SEVERITY; HODGKIN DISEASE; HUMAN; MEDICAL LITERATURE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGNOSIS; RADIATION DOSE; RADIATION FIELD; RADIATION INJURY; RATING SCALE; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 52049096915     PISSN: 15461440     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacr.2008.06.016     Document Type: Review

References (53)

1. Mauch P.M. Controversies in the management of early stage Hodgkin's disease. Blood 83 (1994) 318-329
2. Hoppe R.T., Coleman C.N., Cox R.S., Rosenberg S.A., and Kaplan H.S. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 59 (1982) 455-465
3. Mauch P., Tarbell N., Weinstein H., et al. Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 6 (1988) 1576-1583
4. Specht L., Nordentoft A.M., Cold S., Clausen N.T., and Nissen N.I. Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer 61 (1988) 1719-1727
5. Gospodarowicz M.K., Sutcliffe S.B., Clark R.M., et al. Analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone. Int J Radiat Oncol Biol Phys 22 (1992) 859-865
6. Pavlovsky S., Maschio M., Santarelli M.T., et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst 80 (1988) 1466-1473
7. Tubiana M., Henry-Amar M., Carde P., et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 73 (1989) 47-56
8. Cosset J.M., Henry-Amar M., Meerwaldt J.H., et al. The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group. Eur J Cancer 28A (1992) 1847-1850
9. Sutcliffe S.B., Gospodarowicz M.K., Bergsagel D.E., et al. Prognostic groups for management of localized Hodgkin's disease. J Clin Oncol 3 (1985) 393-401
10. Specht L., Gray R.G., Clarke M.J., and Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 16 (1998) 830-843
11. Duhmke E., Franklin J., Pfreundschuh M., et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19 (2001) 2905-2914
12. Farah R., Ultmann J., Griem M., et al. Extended mantle radiation therapy for pathologic stage I and II Hodgkin's disease. J Clin Oncol 6 (1988) 1047-1052
13. Cosset J.M., Henry-Amar M., and Meerwaldt J.H. Long-term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol 2 suppl (1991) 77-82
14. Hancock S.L., Hoppe R.T., Horning S.J., and Rosenberg S.A. Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials. Ann Intern Med 109 (1988) 183-189
15. Henry-Amar M., Hayat M., Meerwaldt J.H., et al. Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group. Int J Radiat Oncol Biol Phys 19 (1990) 1155-1157
16. Mauch P.M., Kalish L.A., Marcus K.C., et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1 (1995) 33-42
17. Ng A.K., Bernardo M.P., Weller E., et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 20 (2002) 2101-2108
18. Abrahamsen J.F., Andersen A., Hannisdal E., et al. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol 11 (1993) 255-261
19. Dores G.M., Metayer C., Curtis R.E., et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 20 (2002) 3484-3494
20. Ng A.K., Bernardo M.V., Weller E., et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100 (2002) 1989-1996
21. Swerdlow A.J., Barber J.A., Hudson G.V., et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 18 (2000) 498-509
22. van Leeuwen F.E., Klokman W.J., Veer M.B., et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 18 (2000) 487-497
23. Swerdlow A.J., Higgins C.D., Smith P., et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 99 (2007) 206-214
24. Hodgson D.C., Koh E.S., Tran T.H., et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 110 (2007) 2576-2586
25. Koh E.S., Tran T.H., Heydarian M., et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol 2 (2007) 13
26. Eich H., Mueller R., Engert A., et al. Comparison of 30 Gy versus 20 Gy involved field radiotherapy after two versus four cycles ABVD in early stage Hodgkin's lymphoma: interim analysis of the German Hodgkin Study Group trial HD10. Int J Rad Oncol Biol Phys 63 (2005) S1
27. Girinsky T., van der Maazen R., Specht L., et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79 (2006) 270-277
28. Hodgson D.C., Pintilie M., Gitterman L., et al. Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 25 (2007) 11-15
29. Carde P., Burgers J.M., Henry-Amar M., et al. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 6 (1988) 239-252
30. Ganesan T.S., Wrigley P.F., Murray P.A., et al. Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital. Br J Cancer 62 (1990) 314-318
31. Mandelli F., Anselmo A.P., Cartoni C., Cimino G., Maurizi Enrici R., and Biagini C. Evaluation of therapeutic modalities in the control of Hodgkin's disease. Int J Radiat Oncol Biol Phys 12 (1986) 1617-1620
32. Mauch P.M., Canellos G.P., Shulman L.N., et al. Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial. J Clin Oncol 13 (1995) 947-952
33. Wirth A., Byram D., Chao M., et al. Long term results of mantle irradiation (MRT) alone in 261 patients with clinical stage I-II supradiaphragmatic Hodgkin's disease. Int J Radiat Oncol Biol Phys 39 (1997) 174
34. Noordijk E.M., Carde P., Hagenbeek A., et al. Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin's disease. Six-year results of the EORTC-GPMC controlled clinical trials "H7-VF," "H7-F" and "H7-U.". Int J Radiat Oncol Biol Phys 39 (1997) 173
35. Engert A., Franklin J., Eich H.T., et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 25 (2007) 3495-3502
36. Press O.W., LeBlanc M., Lichter A.S., et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 19 (2001) 4238-4244
37. Noordijk E.M., Carde P., Dupouy N., et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24 (2006) 3128-3135
38. Ferme C., Eghbali H., Meerwaldt J.H., et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 357 (2007) 1916-1927
39. Horning S.J., Hoppe R.T., Breslin S., Bartlett N.L., Brown B.W., and Rosenberg S.A. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 20 (2002) 630-637
40. Engert A., Schiller P., Josting A., et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21 (2003) 3601-3608
41. Ferme C., Eghbali H., Hagenbeek A., et al. MOPP/ABV hybrid and irradiation in unfavorable supradiaphragmatic clinical stages I-II Hodgkin's disease: comparison of three treatment modalities. Preliminary results of the EORTC-GELA H8-U 244 American Society of Hematology randomized trial in 995 patients. Blood 96 (2000) A576
42. Bonadonna G., Bonfante V., Viviani S., Di Russo A., Villani F., and Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 22 (2004) 2835-2841
43. Nachman J.B., Sposto R., Herzog P., et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20 (2002) 3765-3771
44. Laskar S., Gupta T., Vimal S., et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?. J Clin Oncol 22 (2004) 62-68
45. Straus D.J., Portlock C.S., Qin J., et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104 (2004) 3483-3489
46. Meyer R.M., Gospodarowicz M.K., Connors J.M., et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23 (2005) 4634-4642
47. Noordijk E.M., Thomas J., Ferme C., et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). J Clin Oncol 23 (2005) 6505
48. Gallamini A., Hutchings M., Rigacci L., et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25 (2007) 3746-3752
49. Hutchings M., Loft A., Hansen M., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 (2006) 52-59
50. Hutchings M., Mikhaeel N.G., Fields P.A., Nunan T., and Timothy A.R. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16 (2005) 1160-1168
51. Zinzani P.L., Tani M., Fanti S., et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 17 (2006) 1296-1300
52. Picardi M., De Renzo A., Pane F., et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leukemia Lymphoma 48 (2007) 1721-1727
53. Nogova L., Reineke T., Eich H.T., et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16 (2005) 1683-1687